Genprex, Inc. filed its Form 10-Q for the quarterly period ended September 30, 2026 with the U.S. Securities and Exchange Commission on November 13, 2026, reporting a net loss of $4,236,725 for the third quarter and disclosing a significant increase in cash and shares outstanding.

Key Highlights

  • Net loss of $4,236,725 for the three months ended September 30, 2026, compared to a net loss of $3,799,240 in the same period of 2025, according to the filing.
  • Nine-month net loss of $13,145,839 for the period ended September 30, 2026, versus $12,438,742 for the same period in 2025.
  • Cash and cash equivalents of $15,347,276 as of September 30, 2026, up from $7,830,855 at December 31, 2025.
  • Common shares outstanding of 1,219,141 as of September 30, 2026, rising from 149,811 at December 31, 2025, with 1,334,753 shares outstanding as of November 9, 2026.
  • Accumulated deficit of $184,174,235 as of September 30, 2026, compared to $171,028,396 at December 31, 2025.
  • Total operating expenses of $4,270,900 for Q3 2026, including $2,743,169 in research and development and $1,527,731 in general and administrative costs.

Genprex Financial Position and Operating Results for the Quarter Ended September 30, 2026

According to the filing, Genprex, Inc. (NASDAQ:GNPX) reported a net loss of $4,236,725 for the three months ended September 30, 2026, an increase from the $3,799,240 net loss recorded in the third quarter of 2025. Total operating expenses for Q3 2026 were $4,270,900, driven by research and development costs of $2,743,169 and general and administrative expenses of $1,527,731. For the nine months ended September 30, 2026, total operating expenses reached $13,249,067, compared to $11,996,987 in the year-earlier period.

The company disclosed that cash and cash equivalents stood at $15,347,276 as of September 30, 2026, up substantially from $7,830,855 at December 31, 2025. The filing attributes the increase primarily to net proceeds from issuances of common stock, which totaled $18,674,610 for the nine months ended September 30, 2026. Net cash used in operating activities for the same nine-month period was $11,212,223, nearly identical to the $11,212,938 used in the comparable 2025 period.

The registrant reported that common shares issued and outstanding grew from 149,811 at December 31, 2025 to 1,219,141 at September 30, 2026. The filing also notes that during Q3 2026 the company issued 72,354 shares as rounding shares to street name accounts in connection with a reverse stock split. Total stockholders' equity was $13,724,399 at September 30, 2026, compared to $7,961,876 at December 31, 2025. The accumulated deficit reached $184,174,235 by quarter end. Net loss per share, basic and diluted, was $(5.30) for Q3 2026, compared to $(109.39) for Q3 2025, reflecting the higher weighted average share count of 799,618 versus 34,730.

What Was Disclosed

Genprex filed its quarterly report covering the period ended September 30, 2026, disclosing a Q3 net loss of $4,236,725, cash of $15,347,276, an accumulated deficit of $184,174,235, and substantial share issuance activity that significantly increased shares outstanding during the nine-month period.